Lineage Cell Therapeutics, Inc. (AMEX: LCTX) is a Healthcare company (Biotechnology) with a market capitalization of $206M. The Maz Rating grades it against the other companies in its sector.
Lineage Cell Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.82, Lineage Cell Therapeutics, Inc. trades at 124.6x trailing earnings, 18.9x sales and 3.1x book value. Over the last twelve months it generated about $11M of revenue and $2M of net income. It runs a gross margin of 95.9%, an operating margin of -280.3% and a net margin of 16.2%. It shows return on equity of 3.1%, return on invested capital of 21.0% and a free cash flow yield of -12.8%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 5.96. Over the past 52 weeks the share price ranged from $0.77 to $1.99, with a beta of 1.69.
Lineage Cell Therapeutics, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 5 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Lineage Cell Therapeutics, Inc. (LCTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 17.8% / 30% · Interest income / Revenue 26.2% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 17.8% / 33% · Receivables / Mkt Cap (36m) 0.53% / 49% · Interest income / Revenue 26.2% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 17.8% / 33.33% · Receivables / Mkt Cap (24m) 0.53% / 33.33% · Interest income / Revenue 26.2% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.20% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 47.9% / 33.33% · Receivables / Avg Assets (4Q) 1.05% / 33.33% · Interest income / Revenue 26.2% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 45.1% / 33.33% · (Cash+Recv) / Total Assets 46.5% / 33.33% · Interest income / Revenue 26.2% / 5% | Fail |
No. As of September 2026, Lineage Cell Therapeutics, Inc. (LCTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Lineage Cell Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 26.2% of each dividend: Lineage Cell Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.